AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure
On December 29, 2017, the Company issued a press release outlining its corporate objectives and financial expectations for the fiscal year 2018. A copy of this press release is attached hereto as Exhibit 99.1.
The information responsive to this Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
* This information shall be deemed to be "furnished" and not filed herewith.
AVADEL PHARMACEUTICALS PLC ExhibitEX-99.1 2 a2018guidance_v5.htm EXHIBIT 99.1 Exhibit Avadel Pharmaceuticals Issues 2018 Corporate OutlookCommercial launch for Noctiva™ on target for second quarter 2018NDA filing for FT218 expected by year-end 2018Total revenues expected to range from $110 – 130 millionDublin,…To view the full exhibit click